TIGIT-CD155 interactions in melanoma: a novel co-inhibitory pathway with potential for clinical intervention
Inozume et al. describe a novel immunosuppressive mechanism in melanoma that is triggered by the interaction between CD155 (expressed by melanomas) and T-cell Ig and ITIM domain (TIGIT) (expressed by tumor infiltrating lymphocytes). This pathway exists in addition to the "classical" co-inh...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
4 January 2016
|
| In: |
The journal of investigative dermatology
Year: 2016, Jahrgang: 136, Heft: 1, Pages: 9-11 |
| ISSN: | 1523-1747 |
| DOI: | 10.1016/j.jid.2015.10.048 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jid.2015.10.048
|
| Verfasserangaben: | Karsten Mahnke and Alexander H. Enk |
| Zusammenfassung: | Inozume et al. describe a novel immunosuppressive mechanism in melanoma that is triggered by the interaction between CD155 (expressed by melanomas) and T-cell Ig and ITIM domain (TIGIT) (expressed by tumor infiltrating lymphocytes). This pathway exists in addition to the "classical" co-inhibitory PD-1-PD-L1 pathway. Hence, the combinatorial blockage of both pathways by specific antibodies resulted in the greatly enhanced effector function of melanoma-specific cytotoxic T cells. Given that CD155-TIGIT signaling exerts potent inhibitory action in different subsets of immune cells and that CD155 is expressed broadly in several tumor entities, this report points toward a novel and promising therapeutic strategy to combine different checkpoint blocking agents for greater success in antitumor therapy. |
|---|---|
| Beschreibung: | Gesehen am 22.05.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1523-1747 |
| DOI: | 10.1016/j.jid.2015.10.048 |